Elevated Adiponectin Antibody Levels in Sera of Patients with Atherosclerosis-Related Coronary Artery Disease, Cerebral Infarction and Diabetes Mellitus

Authors

  • Takaki Hiwasa Department of Biochemistry and Genetics, Graduate School of Medicine, Chiba University, Chiba, Japan
  • Xiao-Meng Zhang Department of Biochemistry and Genetics, Graduate School of Medicine, Chiba University, Chiba, Japan
  • Risa Kimura Department of Biochemistry and Genetics, Graduate School of Medicine, Chiba University, Chiba, Japan
  • Mikiko Ohno Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
  • Po-Min Chen Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
  • Eiichiro Nishi Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
  • Koh Ono Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
  • Takeshi Kimura Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
  • Ikuo Kamitsukasa Department of Neurology, Chiba Rosai Hospital, Chiba, Japan
  • Takeshi Wada Department of Internal Medicine, Chiba Aoba Municipal Hospital, Chiba, Japan
  • Akiyo Aotsuka Department of Internal Medicine, Chiba Aoba Municipal Hospital, Chiba, Japan
  • Seiichiro Mine Department of Neurological Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan
  • Hirotaka Takizawa Port Square Kashiwado Clinic, Kashiwado Memorial Foundation, Chiba, Japan
  • Koichi Kashiwado Department of Neurology, Kashiwado Hospital, Chiba, Japan
  • Minoru Takemoto Department of Clinical Cell Biology and Medicine, Graduate School of Medicine, Chiba University, Chiba, Japan
  • Kazuki Kobayashi Department of Clinical Cell Biology and Medicine, Graduate School of Medicine, Chiba University, Chiba, Japan
  • Harukiyo Kawamura Department of Clinical Cell Biology and Medicine, Graduate School of Medicine, Chiba University, Chiba, Japan
  • Ryoichi Ishibashi Department of Clinical Cell Biology and Medicine, Graduate School of Medicine, Chiba University, Chiba, Japan
  • Koutaro Yokote Department of Clinical Cell Biology and Medicine, Graduate School of Medicine, Chiba University, Chiba, Japan
  • Rika Nakamura Medical Project Division, Research Development Center, Fujikura Kasei Co., Saitama, Japan
  • Go Tomiyoshi Medical Project Division, Research Development Center, Fujikura Kasei Co., Saitama, Japan
  • Natsuko Shinmen Medical Project Division, Research Development Center, Fujikura Kasei Co., Saitama, Japan
  • Hideyuki Kuroda Medical Project Division, Research Development Center, Fujikura Kasei Co., Saitama, Japan

DOI:

https://doi.org/10.33393/jcb.2016.2076

Keywords:

Atherosclerosis, Cardiovascular Disease, Cerebral Infarction, Diabetes Mellitus, Antibody Biomarker

Abstract

Adiponectin secreted from the adipocytes plays pleiotropic, anti-atherosclerotic roles, such as enhancement of insulin secretion and an increase in energy expenditure. The measurement of levels of circulating adiponectin is useful to evaluate the progression of atherosclerosis-related diseases, such as coronary artery disease (CAD), cerebral infarction (CI) and diabetes mellitus (DM). We examined the serum antibody levels against recombinant adiponectin protein via the amplified luminescent proximity homogeneous assay-linked immunosorbent assay (AlphaLISA) method. The results revealed that the antibody levels were significantly higher in patients with CAD, CI and type 2 DM, than in healthy donors. Receiver operating curve analysis showed that the sensitivity was in a range of 41–48% for CAD, CI and DM. Thus, the serum anti-adiponectin antibody levels could be a common marker for atherosclerosis-related diseases.